Print Friendly, PDF & Email

Off-the-Shelf Biopharma Facility that Saves Manufacturers Time and Money

Worldwide demand for antibodies for the treatment of cancer and rheumatoid arthritis, as well as a new generation of vaccines – is increasing, driven by the global ageing population, and the global effort to reduce the incidence of vaccine-preventable diseases.

An antibody is a large protein produced as a part of the trigger for immune responses in your body. When an antibody finds its very specific destination, it attaches to the target and signals an immune response — often deletion of foreign bacteria or viruses. In the case of monoclonal antibodies they can deliver a drug or chemotherapy agent to the site as well. They are used to treat a number of cancers including leukemia’s, non-Hodgkin’s lymphoma, and breast and colorectal cancers as well as autoimmune conditions like rheumatoid arthritis and Crohn’s Disease.

Monoclonal antibodies are able to target a single type of cell and act with a specificity that small molecule drugs cannot.  Each monoclonal antibody recognises one particular protein and works in different ways depending on the protein they are targeting, so different monoclonal antibodies have to be made to target different types of cancer.

Although increasing in popularity, monoclonal antibodies are among the world’s most expensive categories of drugs. The reason for this is that to retrieve the antibodies, the manufacturers must go through a long process of harvesting cell cultures, and then purifying the antibodies. Once this process is completed, the drug-makers have removed proteins and other cell debris present in the cell culture, leaving only the desired antibodies. The production facilities needed to do this are an added cost.

An off-the-shelf solution, KUBio, can help meet the manufacturing needs of cancer-fighting monoclonal antibodies. The flexibility of KUBio mean governments and healthcare providers can improve access to life-saving treatments by manufacturing drugs closer to where they are needed and bringing them to patients more quickly.

“KUBio represents the first manufacturing activity in-country-for-country in the growing economies, supporting the sustainable supply of biologic drugs, reducing import costs and increasing accessibility and affordability to local populations. We are very proud of this product and it could make a real difference to emerging economies,” said Life Sciences Enterprise Solution Leader, Olivier Loeillot.

Innovative solution recognized with Edison’s Awards.

KUBioTM has recently picked up a silver award at this year’s Edison Awards. The award recognizes the innovation KUBio’s preassembled units have shown in providing a fully-functional bioprocessing facility. KUBio’s pre-made modules are assembled at a healthcare provider’s chosen site in around 14-18 months, making it significantly cheaper and faster than constructing a traditional factory.

“The Edison Awards are among the most prestigious accolades honoring excellence in new products so I am thrilled that KUBio won a silver award in the finals,” said Life Sciences Enterprise Solution Leader, Olivier Loeillot.

“It’s exciting to see companies like GE Healthcare continuing Thomas Edison’s legacy of challenging conventional thinking,” said Frank Bonafilia, Edison Awards’ executive director. “Edison Awards recognizes the game‐changing products and services, and the teams that brought them to consumers.”

The Edison Awards, inspired by Thomas Edison’s persistence and inventiveness, recognize innovation, creativity and ingenuity in the global economy. The nominees were judged by more than 3,000 senior business executives and academics from across the US, and the winners announced last month at the Edison Awards Annual Gala in San Francisco.

More Information

KUBio